Advancing drug discovery for schizophrenia.

Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Welnberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, Law AJ, Campbell B, Krystal JH, Moghaddam B, Sawa A, Saw A, Caron MG, George SR, Allen JA, Solis M
Ann N Y Acad Sci. 2011 1236: 30-43

PMID: 22032400 · PMCID: PMC3787879 · DOI:10.1111/j.1749-6632.2011.06216.x

Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, "Advancing Drug Discovery for Schizophrenia" was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.

© 2011 New York Academy of Sciences.

MeSH Terms (13)

Animals Antipsychotic Agents Disease Models, Animal Drug Discovery Epigenomics Genome-Wide Association Study Humans Models, Biological Molecular Targeted Therapy New York Research Research Design Schizophrenia

Connections (1)

This publication is referenced by other Labnodes entities: